NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Medical Devices · USD

NeuroPace, Inc. (NPCE) Stock Analysis

NeuroPace, Inc. (NPCE) is a Medical Devices stock listed on NASDAQ and quoted in US Dollar.

NPCE

$14.90

+$0.15 (+1.02%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare NPCE with… →

NPCE Key Statistics

As of Sep 4, 2026
Trading
Open
$14.62
Previous Close
$14.75
Day's Range
14.47–14.90
52-Week Range
9.22–19.60
Volume
92.30K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.95
Valuation
Market Cap
$511.43M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
4.78
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.48
Financials (FY)
Revenue (FY)
$99.99M+25.13%
Net Income (FY)
−$21.47M
Profit marginThe share of revenue left as profit after all costs and taxes.
−17.86%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
34.32M
1-Year Return
+55.05%
Dividend and dates
Earnings Date
November 3, 2026
Avg Volume
188.31K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

NPCE Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−3.50%
2025+37.98%
2024+8.54%
2023+591.95%
2022−85.22%
2021 (partial year)−59.62%

As of September 4, 2026.

NPCE Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$99.99M−$21.47M−21.5%
2024$79.91M−$27.14M−34.0%
2023$65.42M−$32.96M−50.4%
2022$45.52M−$47.08M−103.4%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$99.99M$77.22M−$16.34M−$21.47M−21.5%
2024$79.91M$59.09M−$21.67M−$27.14M−34.0%
2023$65.42M$48.12M−$27.17M−$32.96M−50.4%
2022$45.52M$32.49M−$40.79M−$47.08M−103.4%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

NPCE Valuation vs Medical Devices Median

Median of 151 stocks
MetricNPCEMedical Devices medianvs median
P/S ratio4.782.9861% above
Profit margin−17.86%−1.69%16.2 pts below

Medians across 151 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 9 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

NeuroPace, Inc. (NPCE) carries a market capitalisation of $511.43M. It is classified in the Medical Devices industry, within the Healthcare sector. The company reports 220 employees.

NPCE last closed at $14.90 on September 4, 2026. That is +$0.15 (+1.02%) against the previous close. Over the past 52 weeks the price has ranged from $9.22 to $19.60. The latest close sits 61.61% above that 52-week low.

Financial Health

In fiscal 2025, NeuroPace, Inc. reported revenue of $99.99M. That is +25.13% against the prior fiscal year, when revenue was $79.91M. The same year closed with a net loss of $21.47M. The reported profit margin is −17.86%. That is 16.2 percentage points below the Medical Devices median of −1.69%. Trailing earnings per share are −0.48.

Across the 4 fiscal years on file, revenue moves from $45.52M in 2022 to $99.99M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 4.78. On price-to-sales that is 60.62% above the Medical Devices median of 2.98. The medians here are taken across 151 Medical Devices companies that report the metric.

The reported beta is 1.95. Daily returns over the trailing 5 years annualize to a volatility of 83.31%. Over the trailing twelve months the price has returned +55.05%. Measured over 5 years, that is −8.93% a year compounded.

Growth & Income

The record shows no dividend for NPCE.

Across the complete calendar years on file, 2023 returned +591.95% and 2022 returned −85.22%. Of the 4 complete calendar years on file, 3 finished higher. 2026 is still running; the price is −3.50% year to date.

Peer Comparison

NeuroPace, Inc. (NPCE) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
NeuroPace, Inc. NPCE $511.43M —
Abbott Laboratories ABT $187.45B 35.1
Medtronic plc. MDT $120.46B 22.9
Stryker Corporation SYK $116.27B 31.9

The Medical Devices industry average P/E ratio is 26.8x. NeuroPace, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$187.45B

 MDT

Medtronic plc.

$120.46B

 SYK

Stryker Corporation

$116.27B

 BSX

Boston Scientific Corporation

$69.27B

 EW

Edwards Lifesciences Corporation

$51.82B

 DXCM

DexCom, Inc.

$33.17B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About NeuroPace, Inc.

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.

Visit website →